DekaBank Deutsche Girozentrale’s Alder Biopharmaceuticals ALDR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-19,800
Closed -$372K 1273
2019
Q3
$372K Sell
19,800
-44,800
-69% -$512K ﹤0.01% 803
2019
Q2
$730K Buy
64,600
+40,400
+167% +$489K ﹤0.01% 850
2019
Q1
$432K Buy
24,200
+4,400
+22% +$57K ﹤0.01% 931
2018
Q4
$203K Sell
19,800
-4,400
-18% -$56.3K ﹤0.01% 964
2018
Q3
$432K Sell
24,200
-600
-2% -$10.8K ﹤0.01% 952
2018
Q2
$391K Hold
24,800
﹤0.01% 962
2018
Q1
$300K Sell
24,800
-500
-2% -$7.23K ﹤0.01% 948
2017
Q4
$234K Hold
25,300
﹤0.01% 924
2017
Q3
$234K Hold
25,300
﹤0.01% 930
2017
Q2
$304K Hold
25,300
﹤0.01% 901
2017
Q1
$533K Sell
25,300
-2,200
-8% -$48.7K ﹤0.01% 731
2016
Q4
$575K Buy
27,500
+2,100
+8% +$54.6K 0.01% 638
2016
Q3
$795K Hold
25,400
0.01% 584
2016
Q2
$618K Buy
25,400
+6,600
+35% +$179K 0.01% 637
2016
Q1
$439K Sell
18,800
-3,300
-15% -$76.4K 0.01% 682
2015
Q4
$752K Buy
22,100
+400
+2% +$13.5K 0.01% 613
2015
Q3
$711K Buy
21,700
+3,300
+18% +$140K 0.01% 610
2015
Q2
$975K Buy
18,400
+600
+3% +$21.8K 0.01% 572
2015
Q1
$514K Buy
+17,800
New +$488K 0.01% 706

DekaBank Deutsche Girozentrale's ALDR Position: Q4 2019 in Review

DekaBank Deutsche Girozentrale sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 19,800 shares — an estimated $372K sold.

DekaBank Deutsche Girozentrale first reported a position in ALDR in Q1 2015 and held it in 19 quarters. The position peaked at $975K in Q2 2015. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

  • DekaBank Deutsche Girozentrale reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 19,800 Alder Biopharmaceuticals shares in Q4 2019, an estimated $372K.
  • DekaBank Deutsche Girozentrale first reported a position in Alder Biopharmaceuticals in Q1 2015 and held it in 19 quarters.
  • DekaBank Deutsche Girozentrale's Alder Biopharmaceuticals position peaked at $975K in Q2 2015.
  • 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2019, filed 4 Feb 2020.